Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza

Laurent Ma Favié, Jean-Luc Murk, Adam Meijer, A Laura Nijstad, Erik M van Maarseveen, Maaike A Sikma

Research output: Contribution to journalArticlepeer-review

Abstract

Favipiravir is a novel antiviral drug approved for influenza treatment in Japan. Little is known about favipiravir pharmacokinetics in critically ill patients. Here, we report a patient with influenza treated with favipiravir and undergoing continuous venovenous haemofiltration (CVVH) on the Intensive Care Unit of a tertiary hospital in the Netherlands. Pharmacokinetic analyses showed increased clearance and decreased plasma levels compared to healthy volunteers. CVVH has no clinically relevant contribution to total clearance. Despite susceptibility to favipiravir, the influenza virus was not cleared. A multi-disciplinary approach is needed to ensure optimal favipiravir treatment in critically ill patients.

Original languageEnglish
Pages (from-to)457-461
Number of pages5
JournalAntiviral therapy
Volume23
Issue number5
DOIs
Publication statusPublished - 2018

Keywords

  • Amides/pharmacokinetics
  • Antiviral Agents/pharmacokinetics
  • Critical Illness
  • Fatal Outcome
  • Hemofiltration/methods
  • Humans
  • Influenza, Human/drug therapy
  • Intensive Care Units
  • Male
  • Middle Aged
  • Netherlands
  • Oseltamivir/administration & dosage
  • Pyrazines/pharmacokinetics
  • Tertiary Care Centers

Fingerprint

Dive into the research topics of 'Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza'. Together they form a unique fingerprint.

Cite this